Kailera Therapeutics, Inc.
NASDAQ:KLRABiotechnology
+$0.51 today
- Market cap
- $1.53B
- Beta
- 0.00
Volume 0.42M
Average 0.80M
KLRA Total Liabilities
Everything the company owes to creditors and other parties.
Kailera Therapeutics, Inc.NASDAQ: KLRA
Total Liabilities · Q2 FY2026 · quarter ended Jun 2026
Total liabilities of $92.95M in Q2 FY2026
Q2 FY2026 total liabilities was $92.95M.
Context
- Total liabilities amounted to 7.7% of total assets at the end of Q2 FY2026.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 1.05B USD
- Year-over-year change
- —
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.05B | — |
Total Liabilities vs competitors
How KLRA compares with its peers on the latest reported figures
- KLRA's Jun 2026 total liabilities of $92.95M is the 2nd highest of the 10 companies compared; the peer median is $30.57M.
- Total liabilities amounts to 7.7% of total assets for KLRA, versus a peer median of 11.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $113.58M | +250.7% | +48.9% | 21.8% | |
KLRAKailera Therapeutics, Inc. | Jun 2026 | $92.95M | — | — | 7.7% |
| Mar 2026 | $78.01M | +1.8% | -29.0% | 78.5% | |
| Jun 2026 | $73.03M | +99.5% | +21.0% | 10.4% | |
| Mar 2026 | $51.64M | +242.0% | +36.5% | 15.4% | |
| Mar 2026 | $30.57M | +299.9% | +43.7% | 11.4% | |
MBXMBX Biosciences, Inc. Common Stock | Sep 2026 | $27.67M | +120.7% | -43.4% | 5.5% |
| Mar 2026 | $27.67M | +5.1% | +11.8% | 59.6% | |
BIOABioAge Labs, Inc. | Mar 2026 | $18.53M | -39.6% | -45.5% | 4.7% |
| Mar 2026 | $8.85M | -61.7% | -2.4% | 9.0% | |
| Peer median (excluding KLRA) | $30.57M | +99.5% | +11.8% | 11.4% | |
Competitors are the stored peer set for KLRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2025 Dec 2025 |
|---|---|
| Cash & Equivalents | 160.27M |
| Short-term Investments | 385.79M |
| Net Receivables | 2.73M |
| Inventory | 0 |
| Other Current Assets | 1.23M |
| Total Current Assets | 557.54M |
| Property, Plant & Equipment (Net) | 12.42M |
| Goodwill | 0 |
| Intangible Assets | 0 |
| Long-term Investments | 106.67M |
| Tax Assets | 0 |
| Other Non-current Assets | 15.67M |
| Total Non-current Assets | 134.76M |
| Total Assets | 692.29M |
| Account Payables | 7.53M |
| Short-term Debt | 0 |
| Tax Payables | 0 |
| Deferred Revenue | 0 |
| Other Current Liabilities | 9.97M |
| Total Current Liabilities | 46.41M |
| Long-term Debt | 0 |
| Deferred Tax Liabilities | 0 |
| Deferred Revenue (Non-current) | 0 |
| Other Non-current Liabilities | 992.63M |
| Total Non-current Liabilities | 1B |
| Total Liabilities | 1.05B |
| Common Stock | 0 |
| Retained Earnings | (368.67M) |
| Accumulated OCI | 229K |
| Other Stockholders Equity | 0 |
| Minority Interest | 0 |
| Total Equity | (356.46M) |
| Total Debt | 10.75M |
| Net Debt | (149.51M) |
Kailera Therapeutics, Inc.
NASDAQ:KLRA
Intrinsic Alpha fair value
Locked
Current Price
$11.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.